MabCure, Inc. Completes a Private Placement in the Aggregate Amount of $1 million

HASSELT, Belgium--(BUSINESS WIRE)--MabCure, Inc. (OTCBB:MBCI) (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities (together, the “Investment Transactions”).

Back to news